Update on Psilocybin and MDMA scheduling

The Scheduling Delegate has decided to seek further advice in relation to psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine]. This will include an independent expert review into the therapeutic value, risks and benefits to public health outcomes for these substances as well as seeking additional advice from the Advisory Committee on Medicines Scheduling following the review.

The final decision will not be announced on 22 April 2021.

Amended timing on the scheduling process for these substances will be published on the TGA website following the completion of the independent review.